Stop-and-go therapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a treatment plan that pauses (stops) and restarts (goes) therapy to control cancer while reducing side effects. It is for people whose nasopharyngeal cancer has spread to multiple sites.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have nasopharyngeal cancer that has spread to more than 5 spots or to more than 2 different organs.
- You must be in fairly good health (able to care for yourself), with a life expectancy of at least 6 months.
- You need to have at least one tumor that can be measured on a scan.
- If you had chemotherapy or radiation in the past, it must have ended at least 6 months before starting this trial.
- You must be willing to use effective birth control during treatment and for 12 months after.
- You cannot be pregnant or breastfeeding, and you must not have an active infection or autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new treatment for people with advanced nasopharyngeal cancer that has spread (stage IVb) and who have not yet had chemotherapy. It aims to see if the experimental treatment is safe and effective as a first option.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
Hear when a new Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.